Business Context and Reporting Period
This Form 8-K was filed on January 19, 2017, by Knight Knox Development Corp. (Nevada). The filing reports a corporate restructuring event approved by a majority of stockholders and the board of directors. The company is headquartered in Dublin, Ireland, with former offices in London, England.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Corporate Name Change: The company name is changing from Knight Knox Development Corp. to Reactive Medical Inc.
- Authorized Capital Increase:
- Common stock increased from 75,000,000 to 150,000,000 shares (par value $0.001).
- Preferred stock authorized at 50,000,000 shares (par value $0.001).
- Regulatory Status: A Certificate of Amendment is being filed with the Nevada Secretary of State with an effective date of February 10, 2017. The amendment is under review by FINRA.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future operations, or specific risk factors. The primary contingency noted is the pending completion of the FINRA review, which must be finalized before the name change and capital increase become fully effective in the market.
Investor Verification Checklist
- Verify the completion of the FINRA review and the official effectiveness of the name change to Reactive Medical Inc.
- Confirm the filing of the Certificate of Amendment with the Nevada Secretary of State.
- Check for subsequent 8-K filings announcing the finalization of the capital structure changes.
- Note the discrepancy between the request metadata (Artego Biosciences) and the filing content (Knight Knox Development Corp./Reactive Medical Inc.).